IRIS
INNAO, Vanessa
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 3.685
NA - Nord America 2.844
AS - Asia 1.744
SA - Sud America 534
AF - Africa 59
Continente sconosciuto - Info sul continente non disponibili 5
OC - Oceania 3
Totale 8.874
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.784
RU - Federazione Russa 1.812
SG - Singapore 751
BR - Brasile 466
CN - Cina 428
IE - Irlanda 427
IT - Italia 364
SE - Svezia 355
PL - Polonia 218
HK - Hong Kong 173
DE - Germania 124
FR - Francia 113
VN - Vietnam 110
IN - India 65
HU - Ungheria 61
GB - Regno Unito 51
FI - Finlandia 37
ID - Indonesia 27
MX - Messico 26
BD - Bangladesh 24
AR - Argentina 23
CA - Canada 23
BE - Belgio 22
IQ - Iraq 21
JP - Giappone 20
TR - Turchia 20
AT - Austria 19
NL - Olanda 19
PK - Pakistan 17
ZA - Sudafrica 17
ES - Italia 13
UA - Ucraina 13
EG - Egitto 12
MA - Marocco 12
LT - Lituania 10
PH - Filippine 10
VE - Venezuela 10
AZ - Azerbaigian 8
EC - Ecuador 8
KR - Corea 8
SA - Arabia Saudita 7
UZ - Uzbekistan 7
CL - Cile 6
CZ - Repubblica Ceca 6
TW - Taiwan 6
BO - Bolivia 5
JO - Giordania 5
KE - Kenya 5
MY - Malesia 5
PE - Perù 5
PS - Palestinian Territory 5
RO - Romania 5
CO - Colombia 4
TN - Tunisia 4
AE - Emirati Arabi Uniti 3
AL - Albania 3
KG - Kirghizistan 3
NI - Nicaragua 3
NP - Nepal 3
PY - Paraguay 3
SK - Slovacchia (Repubblica Slovacca) 3
UY - Uruguay 3
XK - ???statistics.table.value.countryCode.XK??? 3
AU - Australia 2
BH - Bahrain 2
DO - Repubblica Dominicana 2
EU - Europa 2
IL - Israele 2
KZ - Kazakistan 2
LY - Libia 2
MN - Mongolia 2
OM - Oman 2
RS - Serbia 2
SN - Senegal 2
SY - Repubblica araba siriana 2
TH - Thailandia 2
AO - Angola 1
BG - Bulgaria 1
BY - Bielorussia 1
CH - Svizzera 1
CR - Costa Rica 1
DK - Danimarca 1
DZ - Algeria 1
ET - Etiopia 1
GE - Georgia 1
GP - Guadalupe 1
GR - Grecia 1
HN - Honduras 1
IR - Iran 1
JM - Giamaica 1
LB - Libano 1
LK - Sri Lanka 1
LU - Lussemburgo 1
MD - Moldavia 1
NG - Nigeria 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PA - Panama 1
SR - Suriname 1
TG - Togo 1
Totale 8.873
Salva come PNG Salva come JPEG
Città #
Ashburn 561
Moscow 528
Singapore 439
Dublin 427
Chandler 384
Dallas 340
Nyköping 228
Warsaw 212
Hong Kong 172
Messina 165
Beijing 141
San Jose 99
The Dalles 87
Princeton 76
Los Angeles 72
Medford 64
Ann Arbor 63
Budapest 59
Lauterbourg 59
Munich 50
Des Moines 47
New York 45
Jacksonville 42
Dearborn 40
São Paulo 39
Frankfurt am Main 32
Buffalo 28
Ho Chi Minh City 28
Dong Ket 25
Hanoi 23
Tianjin 23
Brussels 22
Santa Clara 22
Council Bluffs 21
Redondo Beach 21
Milan 20
Rio de Janeiro 20
Boardman 18
Cambridge 18
Chennai 18
Nuremberg 18
Wilmington 18
Jakarta 17
Rome 17
Tokyo 17
Belo Horizonte 16
Brooklyn 16
Jinan 16
Turku 16
Woodbridge 16
Nanjing 14
Houston 13
Orem 13
Hangzhou 12
Pune 12
Vienna 12
Bremen 11
Chicago 11
Guangzhou 11
Montreal 11
Hebei 10
Johannesburg 10
Cairo 9
London 8
Ningbo 8
Palermo 8
Paris 8
Porto Alegre 8
San Francisco 8
San Mateo 8
Seattle 8
Shanghai 8
Zhengzhou 8
Baku 7
Boston 7
Brasília 7
Denver 7
Lahore 7
Shenyang 7
Helsinki 6
Hillsboro 6
Istanbul 6
Manchester 6
Mexico City 6
Osasco 6
Poplar 6
Redwood City 6
Stockholm 6
Tashkent 6
Toronto 6
Amman 5
Baghdad 5
Belém 5
Bengaluru 5
Casablanca 5
Curitiba 5
Fortaleza 5
Fuzhou 5
Guarulhos 5
Haikou 5
Totale 5.332
Salva come PNG Salva come JPEG
Nome #
Altered Microrna Expression Profile in the peripheral Lymphomonocytes of Multiple Myeloma Patients with Bisphosphonate-Induced Osteonecrosis of the Jaw 298
Diagnostic utility of Sudoscan for detecting Bortezomib-induced painful neuropathy 251
A multivariate analysis of Multiple Myeloma subtype plasma cells 246
SIRT1 and SIRT2 Expression correlates with advanced disease and bone lesions in Multiple Myeloma 240
Altered microRNA expression profile in the peripheral lymphoid compartment of multiple myeloma patients with bisphosphonate-induced osteonecrosis of the jaw 234
Altered Long Noncoding RNA Expression Profile in Multiple Myeloma Patients with Bisphosphonate-Induced Osteonecrosis of the Jaw 211
Corneal Structural Changes in Nonneoplastic and Neoplastic Monoclonal Gammopathies 198
Disappearance of Acquired Hemophilia A after Complete Remission in a Multiple Myeloma Patient. 193
Adoptive immunotherapy for hematological malignancies: Current status and new insights in chimeric antigen receptor T cells 192
Anticancer Activity of Curcumin and Its Analogues: Preclinical and Clinical Studies 186
Evaluation of the AGE/sRAGE Axis in Patients with Multiple Myeloma 186
A rare spinal localization of gray zone lymphoma without mediastinal involvement: A case report and review of literature 185
Efficacia della chemioterapia convenzionale ad alte dosi in un caso di mieloma multiplo IgM primitivamente doppio-refrattario ai nuovi farmaci 180
A comparative effectiveness study of lipegfilgrastim in multiple myeloma patients after high dose melphalan and autologous stem cell transplant 174
Efficacy and Safety of Ixazomib-Dexamethasone, Ixazomib-Cyclophosphamide-Dexamethasone, Ixazomib-Thalidomide-Dexamethasone and Ixazomib-Bendamustine-Dexamethasone for Elderly Newly Diagnosed Multiple Myeloma (NDMM) Patients: Analysis of the Phase II Randomized Unito-EMN10 Study 173
Changes in serum interleukin-8 and sRAGE levels in multiple myeloma patients 169
Vaccination of multiple myeloma: Current strategies and future prospects 168
Antiresorptive Agents and Anti-Angiogenesis Drugs in the Development of Osteonecrosis of the Jaw. 166
Tumor Circulating Plasma Cells Detected By Flow Cytometric Single Platform Method Correlate with Clinical Response to Therapy and Unfavorable Patiets’ Characteristics 164
Impact of Cumulative Dose of Carfilzomib in Combination with Lenalidomide and Dexamethasone in Relapsed Refractory Myeloma Patients: A Retrospective Real Life Survey of the Sicilian Myeloma Network 162
Telomerase and telomere biology in hematological diseases: A new therapeutic target 161
Feasibility, Tolerability and Efficacy of Carfilzomib, Lenalidomide and Desamethasone (KRD) in Relapsed Refractory Myeloma Patients: A Real-Life Survey of the Sicilian Myeloma Network 160
Myeloma cells induce the accumulation of activated CD94low NK cells by cell-to-cell contacts involving CD56 molecules 157
IXAZOMIB WITH EITHER DEXAMETHASONE, CYCLOPHOSPHAMIDE-DEXAMETHASONE, THALIDOMIDE-DEXAMETHASONE OR BENDAMUSTINE-DEXAMETHASONE FOLLOWED BY IXAZOMIB MAINTENANCE IN ELDERLY NEWLY DIAGNOSED MYELOMA PATIENTS 155
Vaccination strategies in lymphoproliferative disorders: Failures and successes 152
Successful management of a pregnant patient with chronic myeloid leukemia receiving standard dose imatinib 152
The cancer stem cell hypothesis: a guide to potential molecular targets. 146
Standardisation of minimal residual disease in multiple myeloma 145
A rare pancreatic pseudoaneurysm in patient with acute pancreatitis and multiple myeloma 140
Feasibility, Tolerability and Efficacy of Carfilzomib in Combination with Lenalidomide and Dexamethasone in Relapsed Refractory Myeloma Patients: A Retrospective Real-Life Survey of the Sicilian Myeloma Network 139
Role of the microbiota in hematologic malignancies. 138
Immunoproteasome-selective and non-selective inhibitors: A promising approach for the treatment of multiple myeloma. 137
The metabolomic signature of hematologic malignancies 135
Antitumorigenic action of nelfinavir: Effects on multiple myeloma and hematologic malignancies (Review) 135
Coagulopathy and thromboembolic events in patients with SARS-CoV-2 infection: pathogenesis and management strategies 128
The adipose organ and multiple myeloma: Impact of adipokines on tumor growth and potential sites for therapeutic intervention 125
Extramedullary plasmacytoma of the maxilla simulating a maxillary radicular cyst: Quick diagnosis and management 121
Quality of life outcomes in multiple myeloma patients: a summary of recent clinical trials 117
Diagnostic utility of Sudoscan for detecting bortezomib-induced painful neuropathy: a study on 18 patients with multiple myeloma 113
Post-chemotherapy cognitive impairment in hematological patients: current understanding of chemobrain in hematology 111
Quantitative polymerase Chain reaction profiling of microRNAs in peripheral lymph-monocytes from MGUS subjects 109
Preliminary Results of a Prospective Observational Study to Assess the Prevalence of Gaucher Disease in an Adult Population Affected By MGUS. 108
First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials. 108
Nanobodies and Cancer: Current Status and New Perspectives 107
SIRT2 and SIRT3 expression correlates with redox imbalance and advanced clinical stage in patients with multiple myeloma 107
Immune thrombocytopenia: options and new perspectives 101
Monoclonal antibodies: potential new therapeutic treatment against multiple myeloma. 100
Formaldehyde exposure and acute myeloid leukemia: A review of the literature 96
Reduced Dose-Intensity Subcutaneous Bortezomib Plus Prednisone (VP) Or Plus Cyclophosphamide (VCP) Or Plus Melphalan (VMP) For Newly Diagnosed Multiple Myeloma Patients Older Than 75 Years Of Age 96
Mitochondria-targeted antioxidant SkQ1 for gammopathy-related corneal damage 95
The ST2/interleukin-33 axis in hematologic malignancies: The IL-33 paradox 94
Inflammatory and Anti-Inflammatory Equilibrium, Proliferative and Antiproliferative Balance: The Role of Cytokines in Multiple Myeloma 92
Lenalidomide maintenance with or without prednisone in newly diagnosed myeloma patients: A pooled analysis 89
Therapeutic potential of antagomiRs in haematological and oncological neoplasms 87
New insights into yes-associated protein signaling pathways in hematological malignancies: Diagnostic and therapeutic challenges 86
Potential Role of microRNAs in inducing Drug Resistance in Patients with Multiple Myeloma 82
Selective Inhibitors of Nuclear Export in the Treatment of Hematologic Malignancies 81
Lymphocyte Subsets and Inflammatory Cytokines of Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma 78
Radioprotective agents and enhancers factors. Preventive and therapeutic strategies for oxidative induced radiotherapy damages in hematological malignancies 76
Oncolytic viruses and hematological malignancies: A new class of immunotherapy drugs 75
New orally active proteasome inhibitors in multiple myeloma. 72
Reduced IL-33 plasma levels in multiple myeloma patients are associated with more advanced stage of disease 70
Relationship between mitofusin 2 and cancer. 68
Reviewing the significance of vitamin d substitution in monoclonal gammopathies 67
New frontiers about the role of human microbiota in immunotherapy: The immune checkpoint inhibitors and CAR T-cell therapy era 65
Immune checkpoint inhibitors in multiple myeloma: A review of the literature 64
Promising anti-mitochondrial agents for overcoming acquired drug resistance in multiple myeloma 51
null 19
Totale 9.086
Salva come PNG Salva come JPEG
Categoria #
all - tutte 29.198
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 29.198
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021145 0 0 0 0 0 0 0 0 0 89 14 42
2021/2022486 4 25 8 22 14 11 27 19 22 96 39 199
2022/20231.278 119 135 65 120 65 123 9 70 505 11 35 21
2023/2024335 22 75 28 26 29 62 2 20 1 17 7 46
2024/20251.557 83 32 21 89 91 73 36 243 402 96 173 218
2025/20264.407 231 284 373 249 409 874 624 582 594 187 0 0
Totale 9.086